In this episode of LongeCity interview, host Justin Loew speaks with RJ Tevonian, a researcher at Ichor Therapeutics, about his work with RPTag technology and its potential applications in diagnostics and therapeutic delivery.

Key Points:

RJ Tevonian discusses the promising RPTag technology being developed at Ichor Therapeutics, highlighting its potential in therapeutic delivery and diagnostics. With ongoing data science efforts, the technology could revolutionize how proteins are targeted for treatment.

• Introduction to RPTag Technology: Tevonian explains RPTag as a highly stable, protein-binding scaffold that can target specific proteins in the body, with the potential for oral delivery, unlike typical antibody therapies.
• Therapeutic and Diagnostic Applications: The technology could bind to harmful proteins, such as those related to COVID-19, offering uses in both therapeutic treatments and diagnostics, especially in resource-limited settings.
• Key Advantages Over Antibodies: RPTag is significantly smaller than antibodies, making it easier to target areas in the body that are inaccessible to larger molecules, such as the kidneys.
• Data Science and Predictive Modelling: Tevonian’s research includes using machine learning to analyze binding data, helping to identify key mutations that improve binding efficiency, potentially accelerating drug development.
• Supercomputing and Future Work: With access to supercomputers, Tevonian is comparing predictive models to improve screening efficiency for RPTag applications, aiming to save time and reduce costs in developing clinical targets.
• Career Path Advice: Tevonian encourages aspiring researchers to gain multidisciplinary skills, such as combining biochemistry with programming, to stand out in competitive fields like drug development.